Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1994 Sep 27;91(20):9262–9266. doi: 10.1073/pnas.91.20.9262

Conformational effects of environmentally induced, cancer-related mutations in the p53 protein.

P W Brandt-Rauf 1, R Monaco 1, M R Pincus 1
PMCID: PMC44792  PMID: 7937752

Abstract

The tumor suppressor gene p53 has been identified as the most frequent target of genetic alterations in human cancers. A considerable number of environmentally induced, cancer-related p53 mutations in human tumors have been found in a highly conserved proline-rich sequence of the p53 protein encompassed by amino acid residues 147-158. Using conformational energy analysis based on ECEPP (Empirical Conformational Energy for Peptides Program), we have determined the low-energy three-dimensional structures for this dodecapeptide sequence for the human wild-type p53 protein and three environmentally induced, cancer-related mutant p53 proteins with His-151, Ser-152, and Val-154, respectively. The results suggest that the wild-type sequence adopts a well-defined low-energy conformation and that the mutant peptides adopt well-defined conformations that are distinctly different from the conformation of the wild-type peptide. These results are consistent with experimental conformational studies demonstrating altered detectability of antigenic epitopes in wild-type and mutant p53 proteins. These results suggest that the oncogenic effects of these environmentally induced, cancer-related, mutant p53 proteins may be mediated by distinct local conformational changes in the protein.

Full text

PDF
9262

Images in this article

9265Image
on p.9265

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brandt-Rauf P. W., Bomzer G., Belford D., Pincus M. R. An activating amino acid substitution in the c-abl oncogene protein fails to produce a local conformational change. J Protein Chem. 1991 Aug;10(4):437–441. doi: 10.1007/BF01025258. [DOI] [PubMed] [Google Scholar]
  2. Brandt-Rauf P. W., Carty R. P., Chen J., Avitable M., Lubowsky J., Pincus M. R. Structure of the carboxyl terminus of the RAS gene-encoded P21 proteins. Proc Natl Acad Sci U S A. 1988 Aug;85(16):5869–5873. doi: 10.1073/pnas.85.16.5869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brandt-Rauf P. W., De Vivo I., Dykes D. C., Pincus M. R. Conformational effects of selected cancer-related amino acid substitutions in the p53 protein. J Biomol Struct Dyn. 1992 Oct;10(2):253–264. doi: 10.1080/07391102.1992.10508645. [DOI] [PubMed] [Google Scholar]
  4. Brandt-Rauf P. W., Pincus M. R., Chen J. M., Lee G. Conformational energy analysis of the leucine repeat regions of C/EBP, GCN4, and the proteins of the myc, jun, and fos oncogenes. J Protein Chem. 1989 Oct;8(5):679–688. doi: 10.1007/BF01025608. [DOI] [PubMed] [Google Scholar]
  5. Brandt-Rauf P. W., Rackovsky S., Pincus M. R. Correlation of the structure of the transmembrane domain of the neu oncogene-encoded p185 protein with its function. Proc Natl Acad Sci U S A. 1990 Nov;87(21):8660–8664. doi: 10.1073/pnas.87.21.8660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Brash D. E., Rudolph J. A., Simon J. A., Lin A., McKenna G. J., Baden H. P., Halperin A. J., Pontén J. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10124–10128. doi: 10.1073/pnas.88.22.10124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Caron de Fromentel C., Soussi T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer. 1992 Jan;4(1):1–15. doi: 10.1002/gcc.2870040102. [DOI] [PubMed] [Google Scholar]
  8. Chen J. M., Lee G., Murphy R. B., Carty R. P., Brandt-Rauf P. W., Friedman E., Pincus M. R. Comparison of the computed structures for the phosphate-binding loop of the p21 protein containing the oncogenic site Gly 12 with the X-ray crystallographic structures for this region in the p21 protein and EFtu. A model for the structure of the p21 protein in its oncogenic form. J Biomol Struct Dyn. 1989 Apr;6(5):859–875. doi: 10.1080/07391102.1989.10506518. [DOI] [PubMed] [Google Scholar]
  9. Chiba I., Takahashi T., Nau M. M., D'Amico D., Curiel D. T., Mitsudomi T., Buchhagen D. L., Carbone D., Piantadosi S., Koga H. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene. 1990 Oct;5(10):1603–1610. [PubMed] [Google Scholar]
  10. Dygert M., Gō N., Scheraga H. A. Use of a symmetry condition to compute the conformation of gramicidin S1. Macromolecules. 1975 Nov-Dec;8(6):750–761. doi: 10.1021/ma60048a016. [DOI] [PubMed] [Google Scholar]
  11. Finlay C. A., Hinds P. W., Tan T. H., Eliyahu D., Oren M., Levine A. J. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol. 1988 Feb;8(2):531–539. doi: 10.1128/mcb.8.2.531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gannon J. V., Greaves R., Iggo R., Lane D. P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 1990 May;9(5):1595–1602. doi: 10.1002/j.1460-2075.1990.tb08279.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. doi: 10.1126/science.1905840. [DOI] [PubMed] [Google Scholar]
  14. Iggo R., Gatter K., Bartek J., Lane D., Harris A. L. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet. 1990 Mar 24;335(8691):675–679. doi: 10.1016/0140-6736(90)90801-b. [DOI] [PubMed] [Google Scholar]
  15. Kikuchi-Yanoshita R., Konishi M., Ito S., Seki M., Tanaka K., Maeda Y., Iino H., Fukayama M., Koike M., Mori T. Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Res. 1992 Jul 15;52(14):3965–3971. [PubMed] [Google Scholar]
  16. Kress S., Sutter C., Strickland P. T., Mukhtar H., Schweizer J., Schwarz M. Carcinogen-specific mutational pattern in the p53 gene in ultraviolet B radiation-induced squamous cell carcinomas of mouse skin. Cancer Res. 1992 Nov 15;52(22):6400–6403. [PubMed] [Google Scholar]
  17. Levine A. J., Momand J., Finlay C. A. The p53 tumour suppressor gene. Nature. 1991 Jun 6;351(6326):453–456. doi: 10.1038/351453a0. [DOI] [PubMed] [Google Scholar]
  18. Matlashewski G., Lamb P., Pim D., Peacock J., Crawford L., Benchimol S. Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. EMBO J. 1984 Dec 20;3(13):3257–3262. doi: 10.1002/j.1460-2075.1984.tb02287.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Pincus M. R., Brandt-Rauf P. W. Structural effects of substitutions on the p21 proteins. Proc Natl Acad Sci U S A. 1985 Jun;82(11):3596–3600. doi: 10.1073/pnas.82.11.3596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Pincus M. R., Klausner R. D., Scheraga H. A. Calculation of the three-dimensional structure of the membrane-bound portion of melittin from its amino acid sequence. Proc Natl Acad Sci U S A. 1982 Aug;79(16):5107–5110. doi: 10.1073/pnas.79.16.5107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ponnuswamy P. K., Warme P. K., Scheraga H. A. Role of medium-range interactions in proteins. Proc Natl Acad Sci U S A. 1973 Mar;70(3):830–833. doi: 10.1073/pnas.70.3.830. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Shah D., Chen J. M., Carty R. P., Pincus M. R., Scheraga H. A. Correlation of beta-bend conformations of tetrapeptides with their activities in CD4-receptor binding assays. Int J Pept Protein Res. 1989 Oct;34(4):325–332. doi: 10.1111/j.1399-3011.1989.tb01582.x. [DOI] [PubMed] [Google Scholar]
  23. Soussi T., Caron de Fromentel C., May P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene. 1990 Jul;5(7):945–952. [PubMed] [Google Scholar]
  24. Stratton M. R., Moss S., Warren W., Patterson H., Clark J., Fisher C., Fletcher C. D., Ball A., Thomas M., Gusterson B. A. Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene. Oncogene. 1990 Sep;5(9):1297–1301. [PubMed] [Google Scholar]
  25. Stürzbecher H. W., Addison C., Jenkins J. R. Characterization of mutant p53-hsp72/73 protein-protein complexes by transient expression in monkey COS cells. Mol Cell Biol. 1988 Sep;8(9):3740–3747. doi: 10.1128/mcb.8.9.3740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Tanaka S., Scheraga H. A. Theory of the cooperative transition between two ordered conformations of poly(L-proline). I. Phenomenological theory. Macromolecules. 1975 Jul-Aug;8(4):494–503. doi: 10.1021/ma60046a023. [DOI] [PubMed] [Google Scholar]
  27. Vähäkangas K. H., Samet J. M., Metcalf R. A., Welsh J. A., Bennett W. P., Lane D. P., Harris C. C. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet. 1992 Mar 7;339(8793):576–580. doi: 10.1016/0140-6736(92)90866-2. [DOI] [PubMed] [Google Scholar]
  28. Zimmerman S. S., Pottle M. S., Némethy G., Scheraga H. A. Conformational analysis of the 20 naturally occurring amino acid residues using ECEPP. Macromolecules. 1977 Jan-Feb;10(1):1–9. doi: 10.1021/ma60055a001. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES